ImmunityBio secures Saudi approval for ANKTIVA, fueling Middle East expansion
ImmunityBio (NASDAQ:IBRX) announced Wednesday that the Saudi Food and Drug Authority (SFDA) has approved ANKTIVA® (nogapendekin alfa inbakicept) for the treatment of non-muscle invasive bladder cancer (NMIBC).








-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)